Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Antoine Yver"'
Autor:
Ashley Jaksa, Anthony Louder, Christina Maksymiuk, Gerard T. Vondeling, Laura Martin, Nicolle Gatto, Eric Richards, Antoine Yver, Mats Rosenlund
Publikováno v:
Value in Health. 25:1967-1976
Autor:
Lin Zhang, Yali Liu, Shanu Modi, Sara A. Hurvitz, Yeon Hee Park, Javad Shahidi, Cristina Saura, Junji Tsurutani, Seock-Ah Im, Hiroji Iwata, Yoshinori Ito, Ian E. Krop, Keun Seok Lee, Neelima Denduluri, Kenji Tamura, Toshinari Yamashita, Joohyuk Sohn, Eriko Tokunaga, Caleb Lee, José Baselga, Christophe Perrin, Sung Bae Kim, Kenjiro Aogi, Fabrice Andre, Javier Cortes, Antoine Yver
Publikováno v:
Cancer Research. 81:PD3-06
Background Trastuzumab deruxtecan (T-DXd, DS-8201) is an antibody-drug conjugate with a HER2 antibody, tetrapeptide-based cleavable linker, and a novel topoisomerase I inhibitor payload. DESTINY-Breast01 (NCT03248492) is an open-label, international,
Publikováno v:
Annals of Oncology. 31:430-434
Autor:
Javad Shahidi, Junji Tsurutani, Seock-Ah Im, Yeonhee Park, Shanu Modi, Caleb Lee, Hiroji Iwata, Kenji Tamura, Ian E. Krop, Sara A. Hurvitz, Antoine Yver, Christophe Perrin, Sung Bae Kim, Cristina Saura, Yoshinori Ito, Joohyuk Sohn, Eriko Tokunaga, Toshinari Yamashita, Lin Zhang, Javier Cortes, Neelima Denduluri, Fabrice Andre, Kenjiro Aogi, Keun Seok Lee, Shuquan Chen
Publikováno v:
N Engl J Med
The New England journal of medicine, vol 382, iss 7
The New England journal of medicine, vol 382, iss 7
BACKGROUND: Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic topoisomerase I inhibitor. In a phase 1 do
Autor:
Eriko Tokunaga, Caleb Lee, Hiroji Iwata, Sara A. Hurvitz, Seock-Ah Im, Javier Cortes, Cristina Saura, Lin Zhang, Javad Shahidi, Kenjiro Aogi, Junji Tsurutani, Shanu Modi, Kenji Tamura, Antoine Yver, Ian E. Krop, Fabrice Andre, Christophe Perrin, Keun Seok Lee, Toshinari Yamashita, Shuquan Chen, Yeon Hee Park, Sung-Bae Kim, Neelima Denduluri, Yoshinori Ito, Joohyuk Sohn
Publikováno v:
Cancer Research. 80:GS1-03
Background [Fam-] trastuzumab deruxtecan (T-DXd; formerly DS-8201a) is an antibody-drug conjugate with a HER2 antibody, peptide-based cleavable linker, and a novel topoisomerase I inhibitor payload. In a phase 1 trial, the objective response rate (OR
Autor:
T Garimella, Caleb Lee, Masahiro Sugihara, Junji Tsurutani, Ian E. Krop, Kazuo Tamura, J. Baselga, H. Iwata, Lin Zhang, O Yin, Antoine Yver, Russ Wada, Shanu Modi, S. Takahashi
Publikováno v:
Cancer Research. 79:P6-17
Background DS-8201a is a HER2-targeting antibody-drug conjugate with a high drug-to-antibody ratio of 7 to 8. A novel cleavable peptide-based linker joins the humanized HER2 antibody to a topoisomerase I inhibitor payload. In an ongoing phase 1 study
Publikováno v:
Journal of Clinical Oncology. 40:2562-2562
2562 Background: Anti-PD-L1 antibodies are well-established as potent immune effectors in solid tumors expressing PD-L1 and demonstrate binding to these tumor cells within the TME. By contrast, due to the ubiquitous expression of CD47 on normal cells
Autor:
Ashley, Jaksa, Anthony, Louder, Christina, Maksymiuk, Gerard T, Vondeling, Laura, Martin, Nicolle, Gatto, Eric, Richards, Antoine, Yver, Mats, Rosenlund
Publikováno v:
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 25(12)
The development of accelerated approval programs for high morbidity and unmet need conditions has driven the use of single-arm studies in drug development. Regulatory and health technology assessment (HTA) agencies are recognizing that high-quality e
Autor:
William D Tap, Hans Gelderblom, Emanuela Palmerini, Jayesh Desai, Sebastian Bauer, Jean-Yves Blay, Thierry Alcindor, Kristen Ganjoo, Javier Martín-Broto, Christopher W Ryan, David M Thomas, Charles Peterfy, John H Healey, Michiel van de Sande, Heather L Gelhorn, Dale E Shuster, Qiang Wang, Antoine Yver, Henry H Hsu, Paul S Lin, Sandra Tong-Starksen, Silvia Stacchiotti, Andrew J Wagner, on behalf of the ENLIVEN investigators†
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
Lancet, 394(10197), 478-487. ELSEVIER SCIENCE INC
instname
Lancet, 394(10197), 478-487. ELSEVIER SCIENCE INC
ENLIVEN investigators.
[Background] Tenosynovial giant cell tumour (TGCT), a rare, locally aggressive neoplasm, overexpresses colony-stimulating factor 1 (CSF1). Surgery is standard with no approved systemic therapy. We aimed to evaluate pexidar
[Background] Tenosynovial giant cell tumour (TGCT), a rare, locally aggressive neoplasm, overexpresses colony-stimulating factor 1 (CSF1). Surgery is standard with no approved systemic therapy. We aimed to evaluate pexidar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5fbb97926d3ef05247048cfb81ce296
http://hdl.handle.net/10261/201376
http://hdl.handle.net/10261/201376
Autor:
Junji Tsurutani, Kaku Saito, Masaya Hattori, Cynthia X. Ma, Haeseong Park, Kenji Tamura, Charles H. Redfern, Hiroji Iwata, Toshihiko Doi, Tsutomu Iwasa, Javad Shahidi, Kan Yonemori, Shinichiro Taira, Caleb Lee, S. Takahashi, Yoichi Naito, Shanu Modi, Bob T. Li, JM Fisher, Takahiro Jikoh, Antoine Yver, Y Kawasaki
Publikováno v:
Cancer Research. 78:PD3-07
Background DS-8201a is a HER2 targeting antibody-drug conjugate (ADC) with high drug to antibody ratio (8:1), a novel linker and topoisomerase I inhibitor as the payload. In preclinical studies, DS-8201a showed efficacy against both trastuzumab emtan